CN1295578A - 用于血管生成性疾病成像的药物 - Google Patents

用于血管生成性疾病成像的药物 Download PDF

Info

Publication number
CN1295578A
CN1295578A CN99804710A CN99804710A CN1295578A CN 1295578 A CN1295578 A CN 1295578A CN 99804710 A CN99804710 A CN 99804710A CN 99804710 A CN99804710 A CN 99804710A CN 1295578 A CN1295578 A CN 1295578A
Authority
CN
China
Prior art keywords
replaces
gly
asp
independently
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN99804710A
Other languages
English (en)
Chinese (zh)
Inventor
M·拉约帕德耶
D·S·爱德华
T·D·哈里斯
S·J·海明威
刘爽
P·R·辛格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Pharma Co
Original Assignee
DuPont Merck Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DuPont Merck Pharmaceutical Co filed Critical DuPont Merck Pharmaceutical Co
Publication of CN1295578A publication Critical patent/CN1295578A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasonic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasonic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/227—Liposomes, lipoprotein vesicles, e.g. LDL or HDL lipoproteins, micelles, e.g. phospholipidic or polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Optics & Photonics (AREA)
  • Acoustics & Sound (AREA)
  • General Chemical & Material Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN99804710A 1998-03-31 1999-03-29 用于血管生成性疾病成像的药物 Pending CN1295578A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US8015098P 1998-03-31 1998-03-31
US60/080,150 1998-03-31
US11271598P 1998-12-18 1998-12-18
US60/112,715 1998-12-18

Publications (1)

Publication Number Publication Date
CN1295578A true CN1295578A (zh) 2001-05-16

Family

ID=26763137

Family Applications (1)

Application Number Title Priority Date Filing Date
CN99804710A Pending CN1295578A (zh) 1998-03-31 1999-03-29 用于血管生成性疾病成像的药物

Country Status (20)

Country Link
US (2) US6322770B1 (https=)
EP (1) EP1068224B1 (https=)
JP (1) JP4487019B2 (https=)
KR (1) KR20010042288A (https=)
CN (1) CN1295578A (https=)
AR (1) AR020586A1 (https=)
AT (1) ATE295369T1 (https=)
AU (1) AU5541799A (https=)
BR (1) BR9909420A (https=)
CA (1) CA2324555A1 (https=)
DE (1) DE69925262T2 (https=)
EA (1) EA200001007A1 (https=)
EE (1) EE200000574A (https=)
ES (1) ES2241313T3 (https=)
HU (1) HUP0101468A2 (https=)
IL (1) IL138093A0 (https=)
NO (1) NO20004917L (https=)
PL (1) PL343804A1 (https=)
SK (1) SK13952000A3 (https=)
WO (1) WO1999058162A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101659694B (zh) * 2009-05-06 2012-12-12 河北科技大学 抗肿瘤环五肽化合物及其制备方法
CN115515647A (zh) * 2020-03-31 2022-12-23 财团法人峨山社会福祉财团 用于血栓成像的放射性药物和组合物

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6749853B1 (en) * 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
US6794518B1 (en) 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6989139B2 (en) 2000-02-15 2006-01-24 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
AU2001259961A1 (en) * 2000-05-08 2001-11-20 Interuniversitair Micro-Elektronica Centrum Method and technology for high-throughput lead profiling
US7109167B2 (en) 2000-06-02 2006-09-19 Bracco International B.V. Compounds for targeting endothelial cells, compositions containing the same and methods for their use
US8263739B2 (en) 2000-06-02 2012-09-11 Bracco Suisse Sa Compounds for targeting endothelial cells, compositions containing the same and methods for their use
CA2413957A1 (en) * 2000-06-21 2001-12-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals for use in combination therapy
JP2005538030A (ja) * 2000-06-21 2005-12-15 デュポン ファーマシューティカルズ カンパニー 組み合わせ療法での使用のための血管新生障害の画像診断用医薬
CA2413538A1 (en) * 2000-07-06 2002-01-17 Bristol-Myers Squibb Pharma Company Stable radiopharmaceutical compositions and methods for preparation thereof
EP1337278A2 (en) * 2000-11-27 2003-08-27 Bristol-Myers Squibb Medical Imaging, Inc. Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent
TW593278B (en) 2001-01-23 2004-06-21 Wyeth Corp 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
US7271180B2 (en) * 2001-01-23 2007-09-18 Wyeth 1-Aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
DE60231801D1 (de) 2001-04-23 2009-05-14 Mallinckrodt Inc Tc und re markierte radioaktive glycosylierte octreotid-derivate
US7138104B2 (en) * 2001-08-08 2006-11-21 Bristol-Myers Squibb Company Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent
EP1443963B1 (en) 2001-10-22 2014-05-21 The Scripps Research Institute Antibody targeting compounds
EP1572639A4 (en) * 2002-01-24 2006-08-09 Barnes Jewish Hospital ON INTEGRIN TARGET MEDIUM FOR IMAGE PRESENTATION
US7279150B2 (en) 2002-01-24 2007-10-09 Barnes-Jewish Hospital Chelating agents with lipophilic carriers
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
AU2003278807A1 (en) 2002-03-01 2004-08-13 Bracco International B.V. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
US7985402B2 (en) 2002-03-01 2011-07-26 Bracco Suisse Sa Targeting vector-phospholipid conjugates
US7666979B2 (en) * 2002-03-01 2010-02-23 Bracco International B.V. Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same
US7211240B2 (en) 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US20050250700A1 (en) * 2002-03-01 2005-11-10 Sato Aaron K KDR and VEGF/KDR binding peptides
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
ES2398393T3 (es) * 2002-03-01 2013-03-15 Dyax Corp. Péptidos de unión a KDR y a VEGF/KDR y su uso en diagnóstico y terapia
EP2009676B8 (en) * 2002-05-08 2012-11-21 Phoseon Technology, Inc. A semiconductor materials inspection system
US6961607B2 (en) * 2002-07-31 2005-11-01 Uzgiris Egidijus E Method for assessing myocardial angiogenesis
US20040224986A1 (en) 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
AU2003265898A1 (en) * 2002-09-05 2004-03-29 Genentech, Inc. Infusion catheter having an integrated doppler transducer
US20040047917A1 (en) * 2002-09-06 2004-03-11 Stephen Wilson Drug delivery and targeting with vitamin B12 conjugates
EP1539804B1 (fr) * 2002-09-19 2007-01-03 Centre National De La Recherche Scientifique (Cnrs) Synthese et caracterisation de nouveaux systemes de guidage et de vectorisation de molecules d'interet therapeutique vers des cellules cibles.
WO2004069281A1 (en) * 2003-01-30 2004-08-19 The General Hospital Corporation Bifunctional molecules comprising at least one integrin-binding and their use in imaging and therapy of angiogenesis and related disorders
ES2396368T3 (es) 2003-03-03 2013-02-21 Dyax Corporation Péptidos que se unen específicamente al receptor del HGF (CMET) y usos de los mismos
DE602004024299D1 (de) * 2003-05-12 2010-01-07 Lantheus Medical Imaging Inc Vitronectin rezeptorantagonisten und ihre verwendung als radiopharmazeutika
CA2534426A1 (en) * 2003-08-08 2005-02-17 Barnes-Jewish Hospital Emulsion particles for imaging and therapy and methods of use thereof
US20050112064A1 (en) * 2003-08-12 2005-05-26 Sonya Franklin DNA-dependent MRI contrast agents
WO2005077407A1 (en) * 2004-01-16 2005-08-25 Barnes-Jewish Hospital Targeted atherosclerosis treatment
US20070141267A1 (en) * 2004-02-23 2007-06-21 Sonnenschein Mark F Aqueous-based adhesive for bonding low surface energy substrates
AU2005253962A1 (en) 2004-06-09 2005-12-29 Kereos, Inc. Lipophilic derivatives of chelate monoamides
DE602005000853D1 (de) * 2004-07-02 2007-05-24 Vivactis Nv Messung der Wärme erzeugt durch einen chemischen oder biologischen Prozess.
WO2006094725A1 (en) * 2005-03-10 2006-09-14 Bayer Schering Pharma Aktiengesellschaft Chelators for radioactively labeled conjugates comprising a stabilizing sidechain
JP2008540339A (ja) * 2005-04-29 2008-11-20 ワイス Ｎｏｇｏレセプター機能モチーフおよびそれに関するペプチド模倣物、ならびにそれらを使用する方法
US20070122408A1 (en) * 2005-10-20 2007-05-31 The Scripps Research Institute Fc Labeling for Immunostaining and Immunotargeting
US20070140973A1 (en) * 2005-12-15 2007-06-21 Bristol-Myers Squibb Pharma Company Contrast agents for myocardium perfusion imaging
CA2650574A1 (en) * 2006-04-27 2007-11-08 Barnes-Jewish Hospital Detection and imaging of target tissue
EP2076120A1 (en) * 2006-09-29 2009-07-08 Washington University Combinations for treatment of neovasculature
WO2008073842A1 (en) * 2006-12-08 2008-06-19 Molecular Image Inc. Methods for diagnosis and monitoring of neurologic diseases using magnetic resonance methods
US8194963B2 (en) * 2008-03-10 2012-06-05 Siemens Medical Solutions Usa, Inc. Efficient estimator of pharmacokinetic parameters in breast MRI
CN102088991A (zh) 2008-05-13 2011-06-08 堪萨斯大学 金属提取肽标签和相关方法
US20100178245A1 (en) * 2009-01-13 2010-07-15 Arnsdorf Morton F Biocompatible Microbubbles to Deliver Radioactive Compounds to Tumors, Atherosclerotic Plaques, Joints and Other Targeted Sites
JP2012517447A (ja) 2009-02-10 2012-08-02 ザ スクリプス リサーチ インスティチュート 化学的にプログラムされたワクチン接種法
US9187735B2 (en) 2012-06-01 2015-11-17 University Of Kansas Metal abstraction peptide with superoxide dismutase activity
AU2014241182A1 (en) * 2013-03-27 2015-09-24 Theranos Ip Company, Llc Biological sample processing
CA2910802A1 (en) * 2013-04-12 2014-10-16 Samir El Andaloussi Therapeutic delivery vesicles
DE102013113156A1 (de) * 2013-11-28 2015-05-28 Freie Universität Berlin Verbindung und Verfahren zur selektiven Radiomarkierung von Polypeptiden mittels Festphasensynthese
US12377166B2 (en) * 2021-08-26 2025-08-05 University Of Washington Iron oxide nanoparticle for targeted chemo-immunotherapy

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
DE3360633D1 (en) 1982-02-12 1985-10-03 Unitika Ltd Anti-cancer device
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US5135736A (en) 1988-08-15 1992-08-04 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
IL91933A (en) 1988-10-11 1994-12-29 Univ Southern California Vasoactive immunoconjugates useful for increasing the vascular permeability or the blood supply to neoplastic or otherwise diseased tissues
WO1990005539A1 (en) 1988-11-14 1990-05-31 Brigham And Women's Hospital Antibodies specific for elam-1 and the use thereof
US5376356A (en) 1989-03-14 1994-12-27 Neorx Corporation Imaging tissue sites of inflammation
IL112768A (en) 1989-04-10 1998-06-15 Oncogen Pharmaceutical compositions containing oncostatin m for inhibiting angiogenesis
US5395609A (en) 1989-06-19 1995-03-07 Antisoma Limited Synthetic peptides for use in tumor detection
DK0436005T3 (da) 1989-07-20 1995-07-03 Sandoz Ltd Mærkede polypeptidderivater
IN172208B (https=) 1990-04-02 1993-05-01 Sint Sa
WO1993008210A1 (en) 1991-10-18 1993-04-29 Beth Israel Hospital Association Vascular permeability factor targeted compounds
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
PT627940E (pt) 1992-03-05 2003-07-31 Univ Texas Utilizacao de imunoconjugados para o diagnostico e/ou terapia de tumores vascularizados
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
CN1701814A (zh) 1992-11-13 2005-11-30 马克斯普朗克科学促进协会 作为血管内皮生长因子受体的f1k－1
US5342757A (en) 1992-11-13 1994-08-30 Ludwig Institute For Cancer Research Monoclonal antibodies which specifically binds to endosialin, a 165 Kd glycoprotein found on tumor vascular endothelium, and uses thereof
DE4301871A1 (de) 1993-01-13 1994-07-14 Diagnostikforschung Inst Neue Mittel zur Diagnose von Gefäßerkrankungen
US5744120A (en) 1993-03-30 1998-04-28 The Dupont Merick Pharmaceutical Company Ternary radiopharmaceutical complexes
DE4311023C2 (de) 1993-03-31 1996-05-02 Diagnostikforschung Inst Bifunktionelle chalkogenatom-unterbrochene Chelatbildner von Typ XN¶1¶S¶1¶O¶1¶ für radioaktive Isotope, deren Metallkomplexe, Verfahren zu ihrer Herstellung sowie diese enthaltende pharmazeutische Mittel
ES2114209T3 (es) 1993-07-19 1998-05-16 Resolution Pharm Inc Queladores de radionuclidos de tipo hidrazino que tienen una configuracion n3s.
US5753230A (en) 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
ZA955391B (en) 1994-06-29 1996-02-09 Smithkline Beecham Corp Vitronectin receptor antagonists
DE69519929T2 (de) 1994-07-11 2001-05-23 Board Of Regents, The University Of Texas System Verfahren und zusammensetzungen für die spezifische koagulation von tumorgefässen
IL123164A (en) 1995-08-30 2001-03-19 Searle & Co Meta-guanidine urea thiourea or azacyclic amino benzoic acid derivatives and pharmaceutical compositions containing them
DE19536781A1 (de) 1995-09-21 1997-03-27 Diagnostikforschung Inst Bifunktionelle sulfidhaltige Sulfonamid-Chelatbildner vom Typ XSNS für radioaktive Isotope
DE19536785A1 (de) 1995-09-21 1997-03-27 Diagnostikforschung Inst Bifunktionelle sulfidhaltige Sulfonamid-Chelatbildner vom Typ S¶2¶NY für radioaktive Isotope
US5910300A (en) * 1995-11-01 1999-06-08 Bracco Research S.A. Amphiphilic linkers for coupling administrable diagnostically or physiologically active agents and bioselective targeting compounds
CA2237524A1 (en) 1995-11-14 1997-05-22 Du Pont Pharmaceuticals Company Novel macrocyclic compounds as metalloprotease inhibitors
US6331285B1 (en) * 1996-06-05 2001-12-18 Palatin Technologies, Inc. Structurally determined cyclic metallo-constructs and applications
ZA978758B (en) * 1996-10-02 1999-03-30 Du Pont Merck Pharma Technetium-99m-labeled chelator incorporated cyclic peptides that bind to the GPIIb/IIIa receptor as imaging agents
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
AU4753997A (en) * 1996-10-16 1998-05-11 Burnham Institute, The Magnetic resonance imaging of thrombi
GB9708265D0 (en) 1997-04-24 1997-06-18 Nycomed Imaging As Contrast agents
ES2206689T3 (es) 1996-10-28 2004-05-16 Amersham Health As Agentes de contraste.
DE19725368A1 (de) * 1997-06-16 1998-12-17 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren und deren Verwendung für bildgebende Verfahren
JP2001516055A (ja) * 1997-09-10 2001-09-25 ザ バーナム インスティチュート 腫瘍中の血管形成血管系にホーミングする分子を同定する方法
CA2320339A1 (en) * 1998-02-11 1999-08-19 Resolution Pharmaceuticals Inc. Angiogenesis targeting molecules
WO2000006169A1 (en) 1998-07-29 2000-02-10 Merck & Co., Inc. Integrin receptor antagonists

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101659694B (zh) * 2009-05-06 2012-12-12 河北科技大学 抗肿瘤环五肽化合物及其制备方法
CN115515647A (zh) * 2020-03-31 2022-12-23 财团法人峨山社会福祉财团 用于血栓成像的放射性药物和组合物

Also Published As

Publication number Publication date
IL138093A0 (en) 2001-10-31
WO1999058162A3 (en) 2000-04-06
ATE295369T1 (de) 2005-05-15
KR20010042288A (ko) 2001-05-25
US6322770B1 (en) 2001-11-27
US20020001566A1 (en) 2002-01-03
ES2241313T3 (es) 2005-10-16
NO20004917L (no) 2000-11-02
WO1999058162A2 (en) 1999-11-18
SK13952000A3 (sk) 2001-12-03
EP1068224B1 (en) 2005-05-11
AU5541799A (en) 1999-11-29
BR9909420A (pt) 2001-09-25
EP1068224A2 (en) 2001-01-17
DE69925262D1 (de) 2005-06-16
CA2324555A1 (en) 1999-11-18
JP4487019B2 (ja) 2010-06-23
HUP0101468A2 (hu) 2001-08-28
JP2002514611A (ja) 2002-05-21
NO20004917D0 (no) 2000-09-29
EA200001007A1 (ru) 2001-04-23
DE69925262T2 (de) 2006-02-23
AR020586A1 (es) 2002-05-22
PL343804A1 (en) 2001-09-10
EE200000574A (et) 2002-10-15

Similar Documents

Publication Publication Date Title
CN1295578A (zh) 用于血管生成性疾病成像的药物
US6537520B1 (en) Pharmaceuticals for the imaging of angiogenic disorders
CN1254276C (zh) 作为诊断剂中靶组分的基质金属蛋白酶抑制剂
CN1230441C (zh) 结合整联蛋白的肽衍生物
CN1356913A (zh) 玻连蛋白受体拮抗剂药物
CN1622830A (zh) 肽基化合物
AU2007201609A1 (en) Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent
CN1185116A (zh) 三成分放射药物复合物
CN1122577A (zh) 放射标记的血小板GPIIb/IIIa受体拮抗剂作为诊断血栓栓塞疾病的成象剂
CN1968963A (zh) 基于肽的化合物
CN1298390C (zh) 心脏灌注和玻连蛋白受体靶向成像剂的同时成像
EP1311302A2 (en) Pharmaceuticals for the imaging of angiogenic disorders
US6548663B1 (en) Benzodiazepine vitronectin receptor antagonist pharmaceuticals
CN1582166A (zh) 在联合疗法中应用的玻璃粘连蛋白受体拮抗药物
HK1036458A (en) Pharmaceuticals for the imaging of angiogenic disorders
CN1874792A (zh) 包含基质金属蛋白酶底物的化合物及其使用方法
MXPA00009574A (en) Pharmaceuticals for the imaging of angiogenic disorders
CZ20003353A3 (cs) Farmaceutické sloučeniny pro zobrazování poruch angiogeneze
AU2002243238A1 (en) Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent
HK1107102A (en) Peptide-based compounds

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1036458

Country of ref document: HK